Bristol Myers Squibb moved deeper into China’s oncology R&D ecosystem by signing a broad partnership with Hengrui Pharma, agreeing to pay $600 million upfront for 13 early-stage programs spanning both companies’ pipelines. The deal is structured to be worth up to $15.2 billion in total potential consideration as development and commercial milestones are achieved. Hengrui, long viewed as a pipeline heavyweight, will collaborate with BMS to advance the asset set, with the transaction designed to tap Hengrui’s development engine while giving BMS exposure to additional drug candidates. For BMS, the agreement adds near-term optionality as Western portfolios face patent and competitive pressure; for Hengrui, it reinforces the company’s strategy of expanding global reach through partnering with major multinationals.